Fruits you are wasting your time with this individual.
He talks about bad feeling on this board. But he’s one of the key instigators and clearly lives for creating it.
“ you too are at the bookies with your little stubby pencils”
“That sounds more like a pi talking to fellow pis and less like Moses returning from Mount Sinai bearing the word of God”
Doc D
Below is what I said on January 24th
That is somewhat different than your assertion (blatant misrepresentation) of what I said.
No one can say we will get an update. They can only give a view and a reasoning for that view. If they’re sensible they will reset that expectation following new information.
You seem to think today’s email isn’t new information. I think it offers clues as to when we are likely to get an update. Please note the word “likely” it doesn’t mean we will and it doesn’t mean we will have to wait until Apr - May it’s just my thoughts !!
January 24th post
“I remain of the view that towards end of next month we will have a clearer idea and I’m happy to wait. If the share price drifts I see it as another opportunity to buy because news will likely create an uplift from the current price.”
Move on from your unnecessary nonsense intervention
Doc D
I see that you’re back to your boring Yobish insults creating rows where none are required.
The company quoted H1 for trials. To be it seemed likely we would not therefore get news in Q1
Now we have an update mentioning Q2 and full year results. To me it seems likely I need to reset my expectations to full year results which are normally Apr- May.
If you have a different view that you can explain without responding like a 3 year old feel free to comment.
Market abuse is an offence and can be reported using
https://www.fca.org.uk/market-abuse-reporting-form
Including the poster and their posts
MAR 1.8.3G01/04/2013
The following behaviours are, in the opinion of the FCA , market abuse (dissemination):
The following are examples of behaviour which may amount to market abuse (disseminati
(1) a person posts information on an Internet bulletin board or chat room which contains false or misleading statements about the takeover of a company whose shares are qualifying investments and the person knows that the information is false or misleading;
Descriptions of behaviour that amount to market abuse (dissemination)
MAR 1.8.3G01/04/2013
The following behaviours are, in the opinion of the FCA , market abuse (dissemination):
The following are examples of behaviour which may amount to market abuse (dissemination):
(1) a person posts information on an Internet bulletin board or chat room which contains false or misleading statements about the takeover of a company whose shares are qualifying investments and the person knows that the information is false or misleading;
Worth everyone refreshing their memories from the presentations below
Active 2 220 patients 86% risk reduction from a general trial population before we really knew how to select patients specifically.
Sprinter 41% of the original 630 patients re-evaluated to discover between 46% -80% risk reduction in severe outcomes based purely on evaluating their existing patient profiles.
The company already have many clues as to the patients they need to recruit and Universal helps to confirm that through blood analysis, viral testing and biomarkers. Casanova adds to the picture.
The work they’re are doing in my view is not only to guarantee the correct patient group but to present to BP an absolute gold standard case of symptoms, blood analysis, bio markers. Autoantibody analysis that can be repeated in pre approval clinical trials and post approval use.
https://synairgen.ams3.digitaloceanspaces.com/7th-ISIRV-AVG-Conference-2023-Phillip-Monk.pdf
https://synairgen.ams3.digitaloceanspaces.com/7th-ISIRV-AVG-Conference-2023-Phillip-Monk.pdf
Nice to see today’s Mirimus thread highlights this thread from yesterday.
https://www.pharmavoice.com/news/covid-mystery-gene-therapy/704683/
A shifting biotech focus in infectious disease
The Brooklyn biotech company Mirimus, for instance, is developing a test to screen for the autoantibodies that can contribute to severe COVID infection, potentially helping those at risk take needed precautions, and better monitor and treat the infection if they get sick.
“That is a sign that at least some companies are understanding what’s going on,” Casanova said. ”
Thanks Brand
It will be interesting to see who they partner with in manufacture as that may well be the link into Synairgen.
I’m pretty sure Casanova only license so we have another dependency in our trial deliverable which may well explain why H2 2023 did not happen.
That will obviously be part of a non disclosure agreement until parties agree otherwise.
Jean-Laurent Casanova is the Levy Family Professor at The Rockefeller University
He has identified single-gene inborn errors of type I and type II IFN immunity, as well as auto-antibodies neutralizing type I and type II IFNs, which respectively underlie viral and intra-macrophagic infections. Jean-Laurent became an Academic Editor of the Journal of Experimental Medicine in 2006.
Scientific advisory boards/consulting: ADMA, Celgene, Elixiron Immunotherapeutics, KymeraTX,
“Mirimus”
Patent applications: Inventor on a pending patent application that covers diagnosis of susceptibility to, and treatment of, viral disease and viral vaccines, including Covid-19 and vaccine-associated diseases. This pending patent application is currently not licensed.
Jean-Laurent Casanova is the Levy Family Professor at The Rockefeller University
He has identified single-gene inborn errors of type I and type II IFN immunity, as well as auto-antibodies neutralizing type I and type II IFNs, which respectively underlie viral and intra-macrophagic infections. Jean-Laurent became an Academic Editor of the Journal of Experimental Medicine in 2006.
Scientific advisory boards/consulting: ADMA, Celgene, Elixiron Immunotherapeutics, KymeraTX,
Mirimus.